ÐÂÎÅ×ÊѶ
918²©ÌìÌÃÖÆÒ©WP203A»ñÃÀ¹úFDAÊÚÓèÖÎÁÆÌìðå´¯µÄ¹Â¶ùÒ©È϶¨
ÈÕÆÚ£º
2026Äê04ÔÂ02ÈÕ 15:03
¿ËÈÕ£¬£¬£¬£¬£¬£¬£¬918²©ÌìÌÃÖÆÒ©ÔÚÑÐÐÂÒ©WP203A£¨°¢·¨ÅµëÄ£¬£¬£¬£¬£¬£¬£¬afamelanotide£©»ñµÃÃÀ¹úFDAÊÚÓèµÄÖÎÁÆÌìðå´¯£¨pemphigus£©µÄ¹Â¶ùÒ©×ʸñÈ϶¨¡£¡£¡£¡£¡£¡£¡£¡£ÈÏÕæÈËÕԹڼײ©Ê¿ÌåÏÖ£¬£¬£¬£¬£¬£¬£¬“ÏÖÔÚÎÒÃÇÕýÆð¾¢ÍƽøWP203AÔÚÈ«Çò¹æÄ£µÄÐÂÒ©¿ª·¢£¬£¬£¬£¬£¬£¬£¬ÆÚ´ý¸ü¶àµÄÌìðå´¯»¼ÕßÄܹ»ÔçÈÕÓÃÉÏÕâһеÄÖÎÁÆÑ¡Ôñ¡£¡£¡£¡£¡£¡£¡£¡£”
¹ØÓÚWP203A£¨°¢·¨ÅµëÄ£¬£¬£¬£¬£¬£¬£¬afamelanotide£©
ºÚËØÆ¤ÖÊËØÊÜÌ壨MCR£©ÏµÍ³ÔÚÈËÌåÖÐʩչ×ŶàÖÖÐÄÀí¹¦Ð§£¬£¬£¬£¬£¬£¬£¬°üÀ¨µ÷ÀíÑ×Ö¢·´Ó¦¡¢ÃâÒßϵͳÏìÓ¦¡¢´úл¡¢Ê³ÎïÉãÈëÒÔ¼°×éÖ¯ÐÞ¸´µÈ¡£¡£¡£¡£¡£¡£¡£¡£Õâ¸öϵͳ°üÀ¨ÎåÖÖ²î±ðµÄÊÜÌå——MC1RÖÁMC5R£¬£¬£¬£¬£¬£¬£¬Í¨¹ý¼¤»îÌØ¶¨µÄºÚËØÆ¤ÖÊËØÊÜÌ壬£¬£¬£¬£¬£¬£¬¿ÉÒÔʩչÖî¶à×÷Ó㬣¬£¬£¬£¬£¬£¬ÀýÈçïÔÌϸ°ûÓ¦¼¤¡¢¸ÄÉÆÑ×֢״̬£¬£¬£¬£¬£¬£¬£¬²¢Ôö½ø×éÖ¯ÐÞ¸´¡£¡£¡£¡£¡£¡£¡£¡£WP203AÊÇÒ»ÖÖºÏ³ÉµÄºÚÆ¤ÖÊËØÊÜÌ弤¶¯¼Á£¬£¬£¬£¬£¬£¬£¬Ö÷Ҫͨ¹ý¼¤»îMC1RʩչÖÎÁÆ×÷Ó㬣¬£¬£¬£¬£¬£¬Ïêϸ×÷ÓûúÖÆÌåÏÖΪ£º
1.¶Ô¿¹Ñõ»¯Ó¦¼¤£ºÍ¨¹ýÉϵ÷ת¼Òò×ÓNrf2£¬£¬£¬£¬£¬£¬£¬¾ÀÕý»úÌåµÄ¿¹Ñõ»¯/Ñõ»¯Ê§ºâ£¬£¬£¬£¬£¬£¬£¬´Ó¶ø¼õÇáÑõ»¯Ó¦¼¤¶ÔƤ·ôµÄËðÉË¡£¡£¡£¡£¡£¡£¡£¡£
2.µ÷ÀíÃâÒßÓëÑ×Ö¢£ºÍ¨¹ý×÷ÓÃÓÚºÚËØÆ¤ÖÊËØÊÜÌ壬£¬£¬£¬£¬£¬£¬Ò»·½ÃæÒÖÖÆ¶àÖÖ´ÙÑ×ϸ°ûÒò×Ó£¬£¬£¬£¬£¬£¬£¬ÁíÒ»·½Ãæµ÷ÀíTÁܰÍϸ°û¹¦Ð§²¢ÓÕµ¼¾ßÓп¹Ñ××÷Óõĵ÷ÀíÐÔTϸ°û£¬£¬£¬£¬£¬£¬£¬´Ó¶ø»Ö¸´ÃâÒ߯½ºâ¡£¡£¡£¡£¡£¡£¡£¡£
3.Ôö½øÆ¤·ôÓúºÏ£ºÊ¹ÓúÚËØÆ¤ÖÊËØ»¯ºÏÎï¹ÌÓеÄDZÁ¦£¬£¬£¬£¬£¬£¬£¬Ôö½øÓɼ¬²ãËɽ⵼ÖÂµÄÆ¤·ôÀ£ÑñºÍÉ˿ڵÄÐÞ¸´¡£¡£¡£¡£¡£¡£¡£¡£
ÔÚÃÀ¹ú£¬£¬£¬£¬£¬£¬£¬°¢·¨ÅµëÄÒѱ»ÀÖ³ÉÓ¦ÓÃÓÚÖÎÁƺìϸ°ûÌìÉúÐÔÔ߲߸²¡£¡£¡£¡£¡£¡£¡£¡£¨EPP£©£¬£¬£¬£¬£¬£¬£¬ÆäÁÙ´²Ó¦Óò»µ«ÑéÖ¤ÁËMC1R¼¤¶¯¼ÁµÄÇå¾²ÐÔ£¬£¬£¬£¬£¬£¬£¬¸üÕ¹ÏÖ³öÏÔÖøµÄ¿¹Ñ×DZÁ¦£¬£¬£¬£¬£¬£¬£¬ÎªÍØÕ¹ÆäÔÚÆäËûÑ×Ö¢ÐÔºÍ×ÔÉíÃâÒßÐÔÆ¤·ô²¡ÖеÄÓ¦ÓÃÌṩÁËÓÐÁ¦Ö§³Ö¡£¡£¡£¡£¡£¡£¡£¡£´Ë´ÎFDAÊÚÓèµÄ¹Â¶ùÒ©×ʸñÈ϶¨£¬£¬£¬£¬£¬£¬£¬×÷Ϊ918²©ÌìÌÃÖÆÒ©WP203A¿ª·¢ÁìÓòµÄÒ»²¿·Ö£¬£¬£¬£¬£¬£¬£¬½«½øÒ»²½ÎªWP203A¿ª·¢Ð¼ÁÐÍ¡¢ÐÂ˳Ӧ֢¡¢ÐÂÊг¡µÈÁ¢ÒìÐԽṹÌṩÓÐÁ¦Ö§³ÖÓë°ü¹Ü¡£¡£¡£¡£¡£¡£¡£¡£
¹ØÓÚÌìðå´¯
Ììðå´¯ÊÇÒ»ÀàÓÐÊýµÄÑÏÖØÍþвÈËÀ࿵½¡µÄ×ÔÉíÃâÒßÐÔÆ¤·ôð¤Ä¤´óðåÐÔ¼²²¡£¬£¬£¬£¬£¬£¬£¬ÃâÒßϵͳ¹ýʧµØ¹¥»÷Ƥ·ô±í²ã£¨±íƤ£©ºÍճĤµÄϸ°û£¬£¬£¬£¬£¬£¬£¬µ¼ÖÂÆ¤·ôË®ÅݵÄÐγɡ£¡£¡£¡£¡£¡£¡£¡£ÌåÏÖΪð¤Ä¤ºÍƤ·ôÉÏÆ¤µÄË®ÅݺÍÃÓÀ㬣¬£¬£¬£¬£¬£¬Í¨³£»£»£»£»£»£»£»áÑÏÖØÓ°ÏìÉúÑÄÖÊÁ¿£¬£¬£¬£¬£¬£¬£¬ÉõÖÁ¿ÉÄÜÖÂÃü¡£¡£¡£¡£¡£¡£¡£¡£´ó¶¼Ñ°³£ÐÍÌìðå´¯£¨PV£©»¼Õß×îÏÈ·ºÆð¿ÚÇ»Ë𺦣¬£¬£¬£¬£¬£¬£¬Ëæºó·ºÆðƤ·ô²¡±ä¡£¡£¡£¡£¡£¡£¡£¡£¿£¿£¿£¿£¿ÚÇ»²¡±ä³£¼ûÓÚ¼Õð¤Ä¤ºÍÑʲ¿£¬£¬£¬£¬£¬£¬£¬ÌåÏÖΪһÁ¬ÐÔ¡¢ÌÛÍ´ÐÔÃÓÀûòÀ£Ññ£¬£¬£¬£¬£¬£¬£¬ÑÏÖØÓ°Ïì½øÊ³£»£»£»£»£»£»£»ÉúÖ³Æ÷ð¤Ä¤ºÍÑÛ½áĤҲ¿ÉÄÜÊÜÀÛ¡£¡£¡£¡£¡£¡£¡£¡£Æ¤·ô²¡±äÌåÏÖΪËÉиÐÔË®ðåºÍ´óð壬£¬£¬£¬£¬£¬£¬³£¼ûÓÚÕý³£Æ¤·ôÍâò£¬£¬£¬£¬£¬£¬£¬Ë®ðåÒׯÆË飬£¬£¬£¬£¬£¬£¬ÐγÉÀ©´óÐÔÃÓÀÃÃæ£¬£¬£¬£¬£¬£¬£¬NikolskyÕ÷ÑôÐÔ¡£¡£¡£¡£¡£¡£¡£¡£´ó¶¼»¼ÕßÎÞðþÑ÷Ö¢×´¡£¡£¡£¡£¡£¡£¡£¡£Æ¤ËðºÃ·¢ÓÚÐØ±³²¿¡¢Ã沿¡¢Í·²¿¡¢Ò¸ÎÑ¡¢¸¹¹É¹µ¡¢Íβ¿µÈ¡£¡£¡£¡£¡£¡£¡£¡£ ÏÖÔÚÌìðå´¯¼òÖ±Çв¡ÒòÉÐδÍêÈ«ÆÊÎö£¬£¬£¬£¬£¬£¬£¬µ«ÒÅ´«¡¢ÃâÒßÓëÇéÐÎÒòËØÔÚÌìðå´¯µÄ±¬·¢ÖÐʩչÖ÷Òª×÷Óᣡ£¡£¡£¡£¡£¡£¡£ÒÅ´«ÒòËØÊÇÌìðå´¯µÄÖ÷ҪΣº¦ÒòËØÖ®Ò»£»£»£»£»£»£»£»×ÔÉí¿¹ÌålgG¹¥»÷ÇÅÁ£Ð¾ÌÇÂѰ×Dsg1ºÍ/»òDsg3µ¼ÖÂÆäʧȥճ¸½¹¦Ð§£¬£¬£¬£¬£¬£¬£¬ÊÇÌìðå´¯·¢²¡µÄ½¹µã»úÖÆ¡£¡£¡£¡£¡£¡£¡£¡£
Ììðå´¯µÄÖÎÁÆÊܵ½¸Ã²¡µÄÓÐÊýÐÔ¼°È±·¦Ëæ»ú±ÈÕÕÊÔÑ飨RCTs£©µÄÏÞÖÆ¡£¡£¡£¡£¡£¡£¡£¡£ÏÖÓеÄÖÎÁÆÊÖ¶ÎÏà¶Ô¼òµ¥£¬£¬£¬£¬£¬£¬£¬È«ÉíÐÔÆ¤ÖÊÀà¹Ì´¼ÈÔÈ»ÊÇÖ÷ÒªÖÎÁÆÊֶΣ¬£¬£¬£¬£¬£¬£¬Óë¿Ú·þÁòßòàÑßÊ»òù·ÓËáÀ໯ºÏÎÈçù·ÓËáõ¥»òù·ÓËáÄÆ£©ÍŽáʹÓÃÀ´»º½â¼²²¡Ï£Íû ¡¢ïÔ̲»Á¼·´Ó¦ºÍ¸´·¢ÇéÐΡ£¡£¡£¡£¡£¡£¡£¡£È»¶ø£¬£¬£¬£¬£¬£¬£¬¸ß´ï50%µÄ»¼Õ߻Ḵ·¢£¬£¬£¬£¬£¬£¬£¬65%µÄ»¼Õß»áÂÄÀúÓëÃâÒßÒÖÖÆ¼ÁÏà¹ØµÄÑÏÖØ²»Á¼ÊÂÎñ£¬£¬£¬£¬£¬£¬£¬Ô¼°ëÊý»¼ÕßÔÚ3ÄêºóÈÔÐèÒ»Á¬Àà¹Ì´¼ÖÎÁÆ¡£¡£¡£¡£¡£¡£¡£¡£ÀûÍ×Îôµ¥¿¹Í¨¹ýÕë¶ÔBÁܰÍϸ°ûCD20¿¹Ô»º½âÔçÆÚ¼²²¡Àú³Ì£»£»£»£»£»£»£»¶ÈÆÕÀûÓȵ¥¿¹×÷ΪȫÇòÊ׸öÖÎÁƳÉÈË´óðåÐÔÀàÌìðå´¯£¨BP£©µÄ°ÐÏòÒ©Î£¬£¬£¬£¬£¬£¬Í¨¹ýÒÖÖÆ°×ϸ°û½éËØ-4ºÍ°×ϸ°û½éËØ-13ÐźÅͨ·»º½â¼²²¡Àú³Ì¡£¡£¡£¡£¡£¡£¡£¡£×ÛÉÏ£¬£¬£¬£¬£¬£¬£¬ÏÖÓÐÒ©ÎïÆÕ±é±£´æ»úÖÆ¼òµ¥¡¢Ò׸´·¢¡¢²»Á¼·´Ó¦¶àÇÒ±¬·¢Âʸ߻òÖÎÁÆÓöȸ߰ºµÄ¾ÖÏÞ[9,10]£¬£¬£¬£¬£¬£¬£¬´ó¶¼»¼ÕßµÄÁÙ´²ÖÎÁÆÐèÇóÈÔÑÏÖØÎ´Öª×ã¡£¡£¡£¡£¡£¡£¡£¡£
¹ØÓÚFDA¹Â¶ùÒ©È϶¨
¹Â¶ùÒ©£¨orphan drug£©ÊÇFDAΪÃãÀøÓÐÊý²¡ÖÎÁÆÒ©ÎïµÄ¿ª·¢¶øÉèÁ¢µÄÒ»ÖÖ×ʸñÈ϶¨£¬£¬£¬£¬£¬£¬£¬ÎªÐÂÒ©¿ª·¢ÌṩһϵÁеļ¤Àø£¬£¬£¬£¬£¬£¬£¬°üÀ¨´ÓÒ©Æ·ÉÏÊлñÅúºó×îÏȵÄ7ÄêµÄÊг¡×¨ÓªÈ¨£¨market exclusivity£©¡¢ÐÂÒ©ÉêÇ루NDA£©µÄÓÅÏÈÉóÆÀÉóÅú£¨ÓÐʱ»ú¼ÓËÙÒ©Æ·ÁÙ´²Ñо¿¡¢ÉÏÊеÄÀú³Ì£©¡¢ÁÙ´²¿ª·¢Àú³ÌÖÐÇ×½üÖ¸µ¼ÓëÖ§³Ö£¬£¬£¬£¬£¬£¬£¬ÒÔ¼°ÐÂÒ©×¢²áÓöȵÄÃâÈ¥£¨2025ÄêÃÀ¹úFDAÐÂÒ©×¢²áÉêÇë·ÑԼΪ3100ÍòÈËÃñ±Ò£©¡£¡£¡£¡£¡£¡£¡£¡£
²Î¿¼ÆäËû»ñµÃFDA¹Â¶ùÒ©È϶¨µÄ¡¢Õë¶Ô±£´æÑÏÖØÎ´Öª×ãÁÙ´²ÐèÇóµÄ¼²²¡µÄÒ©Æ·ÇéÐΣ¬£¬£¬£¬£¬£¬£¬ÒÔ¼°WiseGuy Report¡¢±´ÕÜ˹×ÉѯµÈ»ú¹¹µÄ¹ûÕæµ÷ÑÐÊý¾Ý£¬£¬£¬£¬£¬£¬£¬¹«Ë¾Ô¤ÆÚδÀ´Ò©Æ·ÉÏÊк󣬣¬£¬£¬£¬£¬£¬ÓÐÍûÔÚÖйúºÍÃÀ¹úÊг¡ÊµÏÖ°ÙÒÚÈËÃñ±Ò¼¶±ðµÄÄêÏúÊÛ¡£¡£¡£¡£¡£¡£¡£¡£
ÎÄÕÂ×ªÔØ×Ô²ÆÁªÉç
²Î¿¼ÎÄÏ×
[1] Haycock J W, Rowe S J, Cartledge S, et al. Alpha-melanocyte-stimulating hormone reduces impact of proinflammatory cytokine and peroxide-generated oxidative stress on keratinocyte and melanoma cell lines[J]. J Biol Chem, 2000, 275(21):15629-36.
[2] Mehta P, Kaye W, Raymond J, et al. Prevalence of Amyotrophic Lateral Sclerosis - United States, 2015[J]. MMWR Morb Mortal Wkly Rep, 2018, 67(46):1285-1289.
[3] Wang W, Guo D Y, Lin Y J, et al. Melanocortin Regulation of Inflammation[J]. Front Endocrinol (Lausanne), 2019, 10:683.
[4] Auriemma M, Brzoska T, Klenner L, et al. alpha-MSH-stimulated tolerogenic dendritic cells induce functional regulatory T cells and ameliorate ongoing skin inflammation[J]. J Invest Dermatol, 2012, 132(7):1814-24.
[5] Bystryn J C, Rudolph J L. Pemphigus[J]. Lancet, 2005, 366(9479):61-73.
[6] Murrell D F, Dick S, Ahmed A R, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus[J]. J Am Acad Dermatol, 2008, 58(6):1043-6.
[7] Herbst A, Bystryn J C. Patterns of remission in pemphigus vulgaris[J]. J Am Acad Dermatol, 2000, 42(3):422-7.
[8] Bohm M, Luger T. Are melanocortin peptides future therapeutics for cutaneous wound healing?[J]. Exp Dermatol, 2019, 28(3):219-224.
[9] Minder E I, Barman-Aksoezen J, Schneider-Yin X. Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic Disorders[J]. Clin Pharmacokinet, 2017, 56(8):815-823.
[10] Understanding the Unmet Needs of the Pemphigus & Pemphigoid Community. IPPF Externally-Led Patient-Focused Drug Development Meeting, January 25, 2023
[11] https://www.gelonghui.com/p/2071680
[12] https://pre.gelonghui.com/p/2502356
[13] https://www.wiseguyreports.com/cn/reports/mucous-membrane-pemphigoid-treatments-market
Ïà¹ØÍÆ¼ö